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Case presentation
Hypophysitis is a rare condition describing inflamma-
tion of the pituitary gland. The disorder may be pri-
mary, involving the pituitary gland itself, or secondary, 
due to other diseases or drugs. The incidence of primary 
hypophysitis is one case per 9 million [1]; however, new 
forms of the condition are increasingly diagnosed and 
the actual occurrence appears to be higher. Symptoms 
are connected with the presence of a pathological mass 
in the pituitary area and hormonal abnormalities. The 
diagnosis is based on clinical presentation, laboratory 
tests, and imaging. Deficiency of ACTH is found in 60% 
of cases, followed by deficits of LH/FSH in 52%, TSH in 
52%, ADH in 39%, GH in 38%, and a high PRL level in 
37% of cases [2]. Magnetic resonance remains the gold 
standard for imaging. The homogenous enhancement 
of the pituitary gland, thickening of a non-deviated 
stalk, and a missing posterior lobe signal in a T1 modal-
ity are the most characteristic radiological changes [3]. 
Hormonal substitution is the cornerstone of therapy. 
In cases with severe neurological symptoms, high-dose 
steroids or other immunosuppressant drugs are used. 
Surgery and radiotherapy are options for patients with 
significant consequences of mass-effect and those resis-
tant to pharmacological treatment. Hypophysitis often 
leads to atrophy of the pituitary gland. More than 70% 
of patients require long-term hormonal substitution [4].
A 22-year-old patient without a significant past 
medical history was admitted to a regional hospital with 
a four-month history of excessive thirst and frequent 
urination. The occurrence of polydipsia and polyuria 
was associated with respiratory tract infection. The 
patient’s hobbies included amateur kickboxing, but he 
denied any head trauma. Based on a water deprivation 
test, diabetes insipidus was diagnosed, with substantial 
improvement in symptom control after administration 
of desmopressin. MR of the pituitary area revealed 
a thickened non-deviated stalk of 4.5 mm and a miss-
ing posterior pituitary lobe signal. During several 
hospitalisations in the Endocrinology Department, 
gonadal and somatotropic axis insufficiencies as well as 
mild hyperprolactinaemia were discovered. Adequate 
control of diabetes insipidus was confirmed. Thyroid 
and adrenal gland function were unaffected. To exclude 
secondary causes of the observed symptoms, multiple 
imaging and biochemical studies were performed with 
unremarkable findings. The patient was diagnosed 
with lymphocytic hypophysitis. In a control MR the 
pituitary stalk was enlarged to 5 × 5 × 5 mm and the 
pituitary lobes did not show any deviations. Due to the 
lack of severe neurological symptoms, treatment was 
continued with desmopressin only. During a follow-up 
assessment, the stalk size normalised to 2.5 × 3 × 3 mm 
on MR (Fig. 1). Prolactin and testosterone values were 
within normal limits. Unfortunately, the diabetes insipi-
dus was persistent, and only a transient improvement 
in IGF-1 levels was observed (Tab. 1). 
This case report shows that diabetes insipidus may 
be the first manifestation of developing hypophy-
sitis. The treatment should be individualised and 
tailored to each case. Patients presenting with mild 
symptoms can be approached with watchful waiting 
as a therapeutic option because hormonal and imaging 
improvements occur during the course of the disease 
[5]. Further research is needed to create algorithms for 
the management of hypophysitis.
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table 1. Hormonal assessment
Hormone [range] IV 2018 VI 2018 IX 2018 I 2019 VI 2019
ACTH [6.0–56.0 pg/mL] 42.0 41.6 45.0 55.0 –
Cortisol — morning 11.6 22.1 18.8 19.3 15.1
TSH [0.27–4.20 uIU/mL] 2.94 2.20 2.27 2.22 3.67
fT4 [12.0–22.0 pmol/L] 13.4 12.5 13.5 16.6 16.65
PRL — morning [50.0–460.0 uIU/mL] 384.0 792.4 263.0 302.1 311.7
LH [1.70–8.60 mIU/mL] 4.07 4.33 4.75 5.18 5.34
FSH [1.5–12.4 mIU/mL] 2.31 2.34 2.92 2.82 2.75
Testosterone [8.64–29.00 nmol/L] 5.66 5.77 5.96 9.09 9.34
GH [0.2–10.0 uIU/mL] 1,3 1.2 0.7 0.6 –
IGF-1 [235.0–408.0 ng/mL] 225.0 164.0 265.0 253.0 215.0
Urine specific gravity [1.005–1.030 g/mL] 1.016 1.021 1.017 1.011 1.003
ACTH — adrenocorticotropic hormone; FSH — follicle-stimulating hormone; fT4 — free thyroxine; GH — growth hormone; IGF-1 — insulin-like growth factor 1;  
LH — luteinising hormone; PRL — prolactin; TSH — thyroid-stimulating hormone
Figure 1. Radiological improvement in a 22-year-old patient with lymphocytic hypophysitis. Magnetic resonance imaging of the pituitary 
area. a. June 2018. B. January 2019. Courtesy of Department of Radiology, University Hospital, Krakow
